Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm

Fig. 1

A schematic representation of the model for the main interactions between the melanoma cancer, the cellular immune system, and the immune checkpoint blocker pembrolizumab. The model is based on the following assumptions: tumor cells stimulate antigen-presenting cells, APCs, depending on the tumor immunogenicity; functional APCs activate effector CD8+ T cells, which may eliminate tumor cells; tumor infiltrating lymphocytes, TILs, become exhausted, independently of the tumor cells elimination; tumor growth is determined by its net growth rate and by the rate of its destruction by Effector TILs; immunotherapy extends the activation of effector TILs, and reduces their exhaustion. Annotated ellipses represent the dynamic variables of the model, while arrows represent the interaction between them (see legends in the box)

Back to article page